Drugs that contain Ixabepilone
1. List of Ixempra Kit drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7022330 | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jan, 2022
(1 year, 14 days ago) | |
| US6670384 | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jan, 2022
(1 year, 14 days ago) | |
| USRE41393 | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Feb, 2022
(11 months ago) | |
|
US7022330
(Pediatric) | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jul, 2022
(6 months ago) | |
|
US6670384
(Pediatric) | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jul, 2022
(6 months ago) | |
|
USRE41393
(Pediatric) | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Aug, 2022
(5 months ago) | |
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(1 year, 6 months from now) | |
|
US7312237
(Pediatric) | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Feb, 2025
(2 years from now) | |
Market Authorisation Date: 16 October, 2007
Treatment: Method of treating patient comprising mixing first and second vials of product comprising lyophilized ixabepilone to provide an epothilone analog solution, diluting solution with a suitable diluent to prepare intravenous formulation for pt; Method of treating cancer in a patient comprising intravenously administering to the patient ixabepilone diluted in a parenteral diluent; Method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; Lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml; Method of treating breast cancer by administering ixabepilone; A method of treating a cancer responsible to microtubule stabilization by administering ixabepilone; Use of ixabepilone in combination with capecitabine in treatment of metastasis breast cancer
Dosage: INJECTABLE;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic